Not all patients treated on the basis of PET-proven viability benefit from revascularization. Myocardial perfusion reserve (MPR) predicts survival in patients not undergoing revascularization. In the present study, we investigated whether MPR is related to survival in ischemic heart disease (IHD) patients after a PET-driven intervention. Methods: Between 1995 and 2003, 119 consecutive patients with chronic IHD underwent a PETdriven revascularization procedure based on ischemia-viability assessment with PET. Patients were followed for all-cause mortality and major cardiovascular events. Results: One hundred nineteen patients underwent a PET-driven revascularization procedure (67 percutaneous coronary interventions, 52 coronary artery bypass grafts) because of angina complaints. The mean age was 67 6 11 y (96 men, 23 women); global left ventricle MPR was 1.54 6 0.43. MPR intertertile boundaries were 1.34 and 1.67. Significantly more cardiac deaths were observed in the lowest and middle MPR tertiles than in the highest tertile. The age-and sex-corrected hazard ratio for the middle tertile was 8.3 (95% confidence interval, 1.02-68.3) and for the lowest tertile 23.6 (95% confidence interval, 3.1-179) (P 5 0.002). After left ventricular ejection fraction (LVEF) and viability were added to the model, MPR remained significant, with hazard ratios of 6.5 (0.8-54.4) and 18.5 (2.32145.5) (P 5 0.004), whereas neither LVEF nor viability reached significance in this model. Comparable results were found for major adverse cardiac events, with hazard ratios of 3.15 (0.82-12.0) and 8.24 (2.36-28.8) (P 5 0.002). Conclusion: Patients with IHD revascularized on the basis of PET viability assessment who have a low MPR are at risk for cardiac death and subsequent cardiac events. MPR is a more sensitive predictor for cardiac death than LVEF and extent of viability.
PET is a powerful tool to assess myocardial viability.
Therefore, PET is often used in ischemic heart disease (IHD) patients to evaluate which patients should be revascularized. PET has several advantages in this context, because it can be used to simultaneously assess viability, ischemia, and left ventricular function-all important components to guide clinical decision making. It has been shown that patients with viable or hibernating myocardium benefit more from revascularization than those without (1, 2) . However, when patients were randomized to PET-versus SPECTdriven revascularization (3) or PET-driven revascularization versus care as usual, no clear benefit was found (4) . One of the main reasons may have been a low adherence to protocol, as the authors indicated (3, 4) . On the other hand, other factors may have played a role. In this context, myocardial perfusion reserve (MPR) may be a contributing factor.
The importance of MPR has initially been described in patients with dilated and hypertrophic cardiomyopathy (5, 6) . In a previous study, we recently extended these observations to patients with end-stage coronary artery disease and reduced left ventricular function (7) , showing that MPR is a strong predictor of cardiac events and death. This finding was confirmed by others (8) . Until now, it was unknown what the importance of MPR measurements was in patients with IHD amenable to revascularization. One may argue that the revascularization procedure per se will restore epicardial hemodynamics. However, MPR is also determined by microvascular components. Therefore, it would be of clinical importance to evaluate the prognostic value of MPR in IHD patient suitable for revascularization. In the present study, we evaluated whether MPR affected events and mortality in patients with proven hibernating myocardium who subsequently underwent revascularization.
MATERIALS AND METHODS

Patients and Study Design
Subjects with advanced IHD who underwent rest 13 N-ammonia, dipyridamole stress 13 N-ammonia, and gated 18 F-FDG PET between 1995 and 2003 at the PET center of the University Medical Center Groningen for the evaluation of stress-induced ischemia and myocardial viability were eligible. This study prospectively included, with retrospective analysis, 119 subjects who underwent a PET-driven revascularization procedure. Patient data were collected from the hospital information system (Table 1) . PET-driven intervention was defined as any cardiac (surgical or percutaneous) procedure performed within the first 6 mo after the PET study date. The revascularization procedure was based on the extent of ischemia and viability. The choice of percutaneous coronary interventions (PCIs) or coronary artery bypass graft (CABG) was based on PET ischemia and viability data and made during the regular meeting of the heart team. These data included the presence of at least 20% jeopardized myocardium (hibernation or ischemia) in the region supplied by a coronary artery with stenosis (50%), a cutoff value that has been reported to accurately predict functional improvement of left ventricular function (3, 9) .
Endpoints
All causes of mortality were assessed. Cardiac death was defined as sudden death, death after the onset of symptoms suggestive of cardiac ischemia, or death due to heart failure. Cardiac events included cardiac death, myocardial infarction, and non-PET-driven revascularization. Myocardial infarction was defined as an increase in cardiac enzymes (.2 times the upper limit of normal), new pathologic Q waves on the electrocardiogram, or both. A major adverse cardiac event (MACE) was defined as cardiac death, myocardial infarction, PCI, CABG, or hospitalization for an acute coronary syndrome or heart failure. Revascularization was considered to be incomplete if not all targeted vessels could be revascularized during the planned procedure or if, during a scheduled follow-up catheterization, restenosis or graft failure was diagnosed.
PET
The patients underwent dynamic rest 13 N-ammonia (400 MBq), dipyridamole stress 13 N-ammonia (400 MBq), and gated 18 F-FDG (200 MBq) PET using a 1-d protocol, as described previously (10) . Briefly, PET studies were performed after the patients had discontinued vasoactive medication for 5 plasma half-lives and had refrained from caffeinated beverages for a minimum of 12 h. Imaging was performed with the patient supine and used an ECAT 951 positron camera (Siemens CTI). Thirty-one planes were measured simultaneously over a length of 10.8 cm. The measured resolution of the system was 6 mm in full width at half maximum. Data were automatically corrected for accidental coincidence and dead time. Patients were positioned with the help of a rectilinear scan. Photon attenuation was measured using a retractable external ring source filled with 68 Ge/ 68 Ga. Perfusion imaging was performed after dipyridamole had been infused (0.56 mg/kg in 4 min). Imaging was started by injecting 400 MBq of 13 N-ammonia 6 min after the start of dipyridamole infusion and continued for 15 min. To stimulate 18 F-FDG uptake, patients were given 75 g of glucose orally just before scanning or were given 500 mg of acipimox (Nedios; Byk Pharmaceuticals) orally 90 min before scanning to lower circulating free fatty acids (11) . To prevent side effects of acipimox (e.g., skin rash), 250 mg of aspirin were administered orally 5 min before acipimox. In diabetic patients, 18 F-FDG imaging was done with hyperinsulinemic euglycemic glucose clamping (12) . After the 13 N-ammonia data had been acquired, 200 MBq of 18 F-FDG were injected intravenously, followed by a PET dynamic acquisition. The total 18 F-FDG PET acquisition time was 40 min, with the last 20 min acquired in gated mode with 16 frames per cardiac cycle. The length of each gate was based on the current R-R interval. The R-R interval was allowed to vary by 610%. Data were corrected for attenuation using the transmission scan and were reconstructed using filtered backprojection (Hann filter, 0.5 pixels/cycle).
Kinetic Models and Data Analysis
Dynamic parametric polar maps were constructed from the PET data (10) . PET perfusion data at rest were corrected for ratepressure product. Myocardial blood-flow data were corrected for partial-volume effect and spillover and quantified by the model of Hutchins et al. (13) . Briefly, myocardial and blood time-activity curves derived from regions of interest over the heart and ventricular chamber are fitted using a 3-compartment model for 13 Nammonia, yielding rate constants for tracer uptake and retention. The perfusion flow reserve (dipyridamole-to-rest ratio) was calculated by dividing the dipyridamole 13 N-ammonia stress study by the 13 N-ammonia rest study. Data analysis of 18 F-FDG was performed with Patlak analysis (14) . Mismatch was quantified by first normalizing the 18 F-FDG uptake polar map and the dipyridamole blood-flow polar map to their means. Then, a difference polar map was created by subtracting the normalized dipyridamole bloodflow polar map from the normalized 18 F-FDG uptake polar map. Mismatch was calculated as the percentage myocardium above the 95% confidence interval of the normal database, and results were expressed as percentage of the total myocardium. Similarly, matching areas were quantified by constructing a product polar map; the normalized dipyridamole blood-flow polar map was multiplied by the normalized 18 F-FDG uptake polar map. Match was defined as the percentage myocardium below the 95% confidence interval. The extent of mismatching areas (viable myocardium) and matching areas (nonviable myocardium) was calculated from these data as previously described (10) . Using only the stress perfusion images for comparison with 18 F-FDG uptake allows identification of jeopardized myocardium but does not allow differentiation between hibernation and ischemia. From a practical point of view, however, this differentiation may not be that important, because both hibernation and ischemia need to undergo revascularization.
The last frames (20-min acquisition time) of the dynamic gated 18 F-FDG PET studies were summed and transformed into static studies and used for further data analysis with the help of the quantitative gated SPECT program (14) . Left ventricular end-systolic and end-diastolic volumes (LVEDV) and left ventricular ejection fraction (LVEF) were computed using the gated 18 F-FDG images.
Statistical Analysis
Descriptive results are expressed as mean 6 SD. Categoric measures are presented as frequencies with percentages. Differences among the 3 tertiles of MPR were assessed by x 2 analysis or ANOVA and tested for trend. The association between MPR and cardiac death or MACE was examined with Cox proportional hazards regression. Crude and age-and sex-adjusted Cox regression-derived relative risks were estimated for cardiac death and MACE. A multiple Cox regression model was developed using bootstrap selection methods (to avoid an overfit model). The variables that correlated with cardiac death at the 0.15 significance level comprised the full model. Such a significance level has previously been suggested (15) . Two hundred bootstrap samples were selected; stepwise selection of variables was applied to each sample. The final model consisted only of variables selected in at least 140 (70%) of the bootstrap models, a cutoff value that has been used previously (15) . Analyses were performed with SPSS software (version 17.0; SPSS Inc.) and STATA statistical software (release 11.0; StataCorp LP).
RESULTS
Patient Characteristics
Between 1995 and 2003, 119 patients underwent a revascularization procedure based on a 13 N-ammonia rest, dipyridamole stress, and gated 18 F-FDG PET scan. Sixtyseven patients underwent PCI, and 52 underwent CABG. Patient characteristics are shown in Table 1 . Ten percent of the patients were in New York Heart Association class I, 44% in class II, 37% in class III, and 9% in class IV. Overall, the MPR was 1.54 6 0.43 (intertertile boundaries, 1.34 and 1.69). Areas of mismatch were found in 81 patients (68%), areas of matching defects in 116 (96%), and both mismatching and matching defects in 79 (66%). Mean percentage match in the study group was 27% 6 14%, mean percentage mismatch was 13% 6 11%, and mean LVEF was 32% 6 15%. Coronary artery disease was present in the left anterior descending artery in 81% of patients, in the right coronary artery in 58%, and in the circumflex coronary artery in 42%. Significant differences between the 3 MPR tertiles were present for LVEF, LVEDV, and digoxin use. Baseline perfusion was comparable; differences in stress perfusion apparently contributed to the MPR.
Outcome Events
The median follow-up among survivors was 88 mo (range, 1-134 mo). Among the 119 patients in this study, there were a total of 29 deaths (24%), of which 22 (18%) were cardiac deaths. Six patients (5%) experienced a nonfatal myocardial infarction. A total of 24 patients (20%) underwent a non-PET-driven PCI and 5 a CABG (4%) during follow-up. Table 2 summarizes the results of the Cox regression analysis for cardiac death. In the univariate analysis, both LVEF and MPR and end-systolic volume and diabetes had a significant association with cardiac death-an association that remained after adjustment for age and sex. The frequencies obtained after bootstrapping are shown in Table 3 . In the final model, only MPR remained significant, with a hazard ratio of 0.79 (0.70-0.89; P , 0.001), whereas neither LVEF nor viability reached significance in this model.
MPR and Cardiac Death
In addition to viability and extent of mismatch, the success of revascularization was also considered. In 24 of the 119 patients, revascularization was considered incomplete. No differences regarding incomplete revascularization were observed between the 3 tertiles (8, 9, and 7 patients, respectively). Completeness of revascularization did not influence the prognostic value of MPR.
Survival data for each MPR tertile are shown in Figure 1A . Table 4 summarizes the results of the age-and sexadjusted Cox regression analysis for MACE. In the univariate analysis, the parameters significantly associated with cardiac death were MPR, diabetes mellitus, LVEF, and
MPR and MACE
In the lowest and middle MPR tertiles, significantly more MACE were observed than in the highest tertile (Fig. 1B) .
DISCUSSION
Since the identification of hibernating myocardium (16), many PET studies have been performed to assess viability (1,2,4,17-19 ). Besides PET, other imaging modalities may yield diagnostic information on viability (3, 20, 21) . The advantage of PET is that on top of viability, absolute myocardial perfusion can be measured. In addition, MPR can be assessed using vasodilator substances. In the present study, we further expand our previous data (7) to revascularization patients. Interestingly, despite the intervention, MPR remains a strong predictor of survival also in this group, implying that even after restoration of epicardial hemodynamics, preintervention microvascular dynamics remain important. Regional MPR has previously been investigated in a study using MRI 24 h after PCI. In that study, it was shown that regional MPR improved after PCI but did not normalize and that improvement of MPR was better after stenting than after balloon angioplasty (22) . In another study using MRI to assess regional MPR early and late after PCI, it was shown that the initial drop in MPR recovered after 6 mo. These authors argued that the extent of distal embolization may have temporally negatively influenced regional MPR (23) . In our intervention group, more than half of the patients underwent a PCI. As MPR can be assessed repeatedly because of its noninvasive nature, it has been suggested as a tool for monitoring effects of risk factor modification such as lipid-lowering treatment (24) . Whether this translates into improved risk modification and prognostic benefit remains to be elucidated. In a small number of patients undergoing a second PET scan after revascularization, we did not find improved MPR (data not shown). The question remains whether epicardial revascularization has a large effect on the small vasculature. LVEF in our study was low and, as can be expected, did not discriminate with respect to prognosis. Apparently, MPR on top of a low LVEF can be used to further determine prognosis in these patients. We have previously described the relationship between myocardial perfusion and (regional) left ventricular function (25, 26) in heart failure patients. The importance of myocardial perfusion and further development of heart failure as a result of this phenomenon has also been proposed (27, 28) . In heart failure patients with coronary artery disease, the decision on whether to revascularize depends at present on viability (besides coronary anatomy). The present study sheds new light on the revascularization issue: microvascular function also matters. According to the guidelines, revascularization in patients with heart failure should be considered in selected heart failure patients with coronary artery disease. At present, myocardial perfusion (reserve) is not considered in the decision process (29) . The overall 5-y event rate in the 2 higher MPR tertiles was better than the recently published BARI-2D data (30) , and in the middle tertile, these results are comparable to the long-term survival in the original BARI study group (31) . The lower tertile, however, showed a much higher 5-y event.
Our study has several limitations. We did not analyze regional perfusion defects, possibly leading to a dilution of the data. In our patients with known coronary artery disease, an even higher predictive value of regional MPR might be expected. Furthermore, as a result of the large time span during which patients were included, medication regimens and guidelines have been subject to change. The low percentage of patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers can be considered a result of this lengthy time span.
Finally, we did not randomize patients according to MPR. However, because these data are the reflection of standard clinical care we feel this is an important observation adding to recent previous observations (7, 8) .
CONCLUSION
The extent of mismatch is a good predictor of functional recovery (2) . It has also been shown that prognosis can be assessed by preoperative viability assessment (17) . As such, one could argue that a diagnostic work-up to identify patients who would benefit most from revascularization should include viability assessment. In a randomized trial comparing PET-guided care with standard care, no significant benefit was found (4) . It has been suggested that the major explanation for the lack of benefit shown in this study may be found in the large proportion of patients who did not adhere to the PET-indicated strategy (2, 32) , because a post hoc analysis showed 38% fewer events in patients who adhered to the PET recommendations. Our data shed light on another aspect in this patient group. Despite the PETdriven revascularization procedure, the group with the lower MPR did worse: viability combined with MPR-guided strategy may better select patients who will optimally benefit from revascularization. Finally, it would be worthwhile to pursue interventions aiming at improvement or maintenance of coronary vascular function (33, 34) .
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